ArticlePharmacoEconomics2009

Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.

Jeroen P Jansen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.